Defining the value of CD56, CK19, Galectin 3 and HBME-1 in diagnosis of follicular cell derived lesions of thyroid with systematic review of literature
Open Access
- 26 October 2015
- journal article
- review article
- Published by Springer Nature in Diagnostic Pathology
- Vol. 10 (1) , 1-18
Abstract
Nodular follicular lesions of thyroid gland comprise benign and malignant neoplasms, as well as some forms of hyperplasia. “Follicular” refers to origin of cells and in the same time to growth pattern - building follicles. Nodular follicular thyroid lesions have in common many morphological features, therefore attempts were made to define additional criteria for distinction between follicular adenoma, follicular carcinoma and follicular variant of papillary carcinoma. Increasing number of immunohistochemical markers is in the continual process of evaluation. Tissue microarrays incorporating, total 201 cases, out of which 122 malignant and 79 benign follicular lesions, including neoplastic and non-neoplastic, were constructed and immunostained with antibodies to CD56, CK19, Galectin-3, HBME-1. Tissue cores were exclusively being acquired from tumour/lesion on interface with normal thyroid tissue. A systematic review of literature was done for period from the year 2001 to present time. All analysed markers may make a difference between benign lesions/tumours from differentiated thyroid carcinomas (p = <0.01, for all markers). Expression of all markers is significantly higher in papillary carcinoma than in follicular adenoma (p < 0.01). Statistically significant difference in expression of Galectin-3 and CD56 between follicular carcinoma and follicular adenoma was registered (p = 0.043; p = 0.028, respectively). The only marker which expression showed statistically significant difference between adenoma and carcinoma of Hurthle cells was Galectin 3 (p = 0.041). CK19 and HBME-1 were significantly expressed more in papillary carcinoma as compared to follicular carcinoma. Galectin 3 is most sensitive marker for malignancy, while loss of expression of CD56 is very specific for malignancy. Expected co-expression for combination of markers in diagnosis of follicular lesions decreases sensitivity and increases specificity for malignancy.Keywords
Funding Information
- Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja (RS)
This publication has 70 references indexed in Scilit:
- Immunohistochemical markers in the diagnosis of papillary thyroid carcinomas: The promising role of combined immunostaining using HBME-1 and CD56Pathology - Research and Practice, 2013
- Pitfalls in the Diagnosis of Follicular Epithelial Proliferations of the ThyroidAdvances in Anatomic Pathology, 2012
- Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of ChinaDiagnostic Pathology, 2011
- The Loss of the p53 Activator HIPK2 Is Responsible for Galectin-3 Overexpression in Well Differentiated Thyroid CarcinomasPLOS ONE, 2011
- Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinomaJournal of Clinical Pathology, 2010
- Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignanciesBiochemical and Biophysical Research Communications, 2008
- Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: utility of HBME1 combined with CK19 immunostainingLaboratory Investigation, 2006
- Usefulness of HBME‐1, cytokeratin 19 and galectin‐3 immunostaining in the diagnosis of thyroid malignancyHistopathology, 2005
- The Use of a Combination of Galectin-3 and Thyroid Peroxidase for the Diagnosis and Prognosis of Thyroid CancerAmerican Journal of Clinical Pathology, 2004
- Immunohistochemical Diagnosis of Papillary Thyroid CarcinomaLaboratory Investigation, 2001